Tarsus Pharmaceuticals, Inc. TARS Clinical Milestones — Maximum milestone payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:CollaborativeArrangementMaximumMilestonePayment.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s clinical milestones — maximum milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s clinical milestones — maximum milestone payments?
- Tarsus Pharmaceuticals, Inc. (TARS) reported clinical milestones — maximum milestone payments of $4M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s clinical milestones — maximum milestone payments changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s clinical milestones — maximum milestone payments decreased by 0.0% year-over-year, from $4M to $4M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s clinical milestones — maximum milestone payments?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s clinical milestones — maximum milestone payments has grown at a -1.0% compound annual growth rate (CAGR), from $16.5M to $16M.
- What does clinical milestones — maximum milestone payments mean?
- This metric represents the total potential future payments that may be earned upon the successful achievement of all remaining clinical, regulatory, and commercial milestones under existing partnership or licensing agreements. It serves as a measure of the total remaining upside potential embedded within the company's current portfolio of collaborative assets. Monitoring this figure provides insight into the long-term value creation potential tied to the company's pipeline development and external partnerships.